YesWeHack Raises 26 Million Euros to Accelerate Its Growth and International Expansion
11.6.2024 09:00:00 EEST | Business Wire | Press release
YesWeHack, the global Bug Bounty and vulnerability management platform, announces a €26 million Series C funding round.
In a world where cyber risks are more strategic and complex than ever, YesWeHack will use this funding to invest in Artificial Intelligence, launch new innovative solutions and expand its international growth.
The round is led by Wendel, alongside new investors such as Adelie and Seventure Partners, as well as reinvestment from Bpifrance, Open CNP* and Eiffel Investment Group. YesWeHack is also delighted to welcome Renaud Deraison, Co-Founder of Tenable and Senior Advisor to Wendel Growth, to its Board of Directors.
YesWeHack is the leading security testing solution for organisations of all sizes. Its Bug Bounty platform mobilises a community of tens of thousands ethical hackers to test the security of its customers in an agile and cost-effective way, thus reducing their attack surface.
With more than 500 customers across 40 countries, YesWeHack covers all business sectors, including:
- 70% of “CAC 40” ** companies
- Global organisations such as Louis Vuitton, Decathlon and Tencent
- Telecoms companies such as Orange, Ooredoo and Telenor
- Unicorns such as Contentsquare, Doctolib and Blablacar
- Public institutions in countries such as France, Spain, Canada and Singapore
Since its last funding round in 2021, YesWeHack has increased by six times its annual recurring revenue and tripled the number of ethical hackers registered on its platform. The company has also developed integrated pentest and attack surface management solutions, offering customers a unified approach to monitoring their online risks and vulnerabilities.
Guillaume Vassault-Houlière, CEO and Co-Founder of YesWeHack, commented: “This funding round is a vote of confidence in our commitment to excellence and our ambitious vision. Thanks to this investment, YesWeHack will deliver even higher levels of customer satisfaction and continue developing innovative solutions in one of the most dynamic segments of cybersecurity. We would like to thank our investors, both longstanding and new, and are honoured by their trust.”
Antoine Izsak, Head of Growth Equity at Wendel, said: “Bug bounty is now recognised as a must by some of the companies most exposed to the cyber threat. We are delighted to be working with the European leader YesWeHack, which stands out for its quality of service, compliance with regulations and the relevance of its technological roadmap for customers who are increasingly overwhelmed by the growing volume of vulnerabilities."
Renaud Deraison, Co-Founder of Tenable, Senior Advisor to Wendel Growth and new member of the Board of Directors added:"YesWeHack's community of experts is one of the most qualified in the world to continuously test the security of its customers' digital infrastructure. I'm honoured to join YesWeHack's Board of Directors and look forward to contributing to the company's mission alongside Guillaume and his team."
*The Corporate Venture Capital fund of CNP Assurances.
**The CAC 40 is Paris’ main stock market index.
About YesWeHack
YesWeHack is a leading Bug Bounty and Vulnerability Management Platform. Founded by ethical hackers in 2015, YesWeHack connects organisations worldwide to tens of thousands of ethical hackers, who uncover vulnerabilities in websites, mobile apps, connected devices and digital infrastructure.
Our Bug Bounty Programs benefit from in-house triage, personalised support, a customisable model and results-based pricing. Clients include Tencent, Swiss Post, Telenor, Ooredoo, Orange, the French Ministry of Armed Forces and several other governments worldwide.
The YesWeHack platform offers a range of integrated, API-based solutions: Bug Bounty (crowdsourcing vulnerability discovery), Vulnerability Disclosure Policy (creating and managing a secure channel for external vulnerability reporting), Pentest Management (managing pentest reports from all sources) and Attack Surface Management (continuously mapping online exposure and detecting attack vectors).
For more information, visit: www.yeswehack.com
This transaction was carried out with the expert support of Trachet Ltd.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610793319/en/
Contact information
Press
press@yeswehack.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom